University of Virginia Pioneers Focused Ultrasound for Temporary Blood-Brain Barrier Opening, Redefining Drug Size Impact on Delivery

September 6, 2026

Physics World USA

Overview

Researchers at the University of Virginia have developed a pioneering method using focused ultrasound (FUS) to temporarily open the blood-brain barrier (BBB) for drug delivery to the brain. Utilizing MRI physics, their study challenges the “smaller is better” assumption by investigating how drug size impacts FUS-mediated delivery, offering new insights for optimizing drug design. This technique involves injecting gas-filled microbubbles and using FUS to induce their oscillation, creating transient gaps in the BBB.

In Depth

Key Findings

Researchers at the University of Virginia have demonstrated the potential of focused ultrasound (FUS) as an innovative method to temporarily open the blood-brain barrier (BBB) and facilitate drug delivery to the brain, addressing a long-standing challenge in neuroscience. Their work, employing advanced MRI physics, meticulously investigated how drug size influences FUS-mediated delivery, providing crucial insights that challenge the conventional wisdom that “smaller drugs are better” for brain penetration.

Technical / Clinical Details

The Blood-Brain Barrier Challenge: The BBB serves as a crucial physiological barrier protecting the brain from harmful substances in circulating blood. However, it concurrently obstructs many therapeutic agents from reaching the brain, making drug development for CNS disorders like Alzheimer’s, Parkinson’s, and brain tumors exceptionally difficult.
FUS-Mediated BBB Opening: The technique begins with the intravenous injection of gas-filled microbubbles into the patient. Subsequently, focused ultrasound waves are externally directed through the skull to specific regions of the brain. The ultrasound energy causes the microbubbles to undergo localized expansion and contraction, a phenomenon known as cavitation. This cavitation creates transient, microscopic gaps in the tight junctions between the endothelial cells that form the BBB. These gaps typically close within a few hours, allowing therapeutic agents to perfuse into the brain tissue.
Re-evaluating Drug Size Impact: The University of Virginia team utilized sophisticated MRI physics and imaging techniques to track the behavior of drugs as they traversed the opened BBB in real-time. Their findings suggest that drugs within a specific size range might exhibit optimal delivery efficiency, indicating that simply being smaller is not always superior. This discovery opens new avenues for optimizing drug design strategies for FUS-enabled drug delivery systems.

Background & Context

Central Nervous System (CNS) disorders often suffer from limited therapeutic options, with the BBB being a primary impediment to drug efficacy. FUS has gained significant attention as a non-invasive technology for BBB opening due to its ability to create localized and temporary openings, potentially reducing the risks associated with more invasive delivery methods. This technology holds immense promise for expanding the pipeline of treatments for a wide array of brain diseases.

Strategic Significance & Outlook

The FUS-mediated BBB opening technology holds transformative potential for delivering therapeutics for various CNS disorders, including Alzheimer’s disease, Parkinson’s disease, brain tumors, and epilepsy. Further research into optimizing drug size and FUS parameters will accelerate the clinical translation of this technology. In the future, FUS may enable precise, personalized drug delivery tailored to individual patient pathologies, marking a significant advancement in targeted brain therapeutics.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.